Core Insights - Artelo Biosciences is strategically positioned for growth in the $16.3 billion glaucoma market through a fully funded clinical study, highlighting its multi-platform biotech pipeline across various therapeutic areas [1][2][4] Pipeline Overview - The company is advancing three clinical-stage programs targeting oncology support, neuropathic pain, and CNS disorders, while also expanding its lead compound into ophthalmology [2][3] - Artelo's pipeline is based on the principle of modulating lipid-signaling pathways, particularly the endocannabinoid system, to achieve therapeutic outcomes without CNS liabilities [5] Key Compounds - **ART27.13**: A peripheral CB1/CB2 agonist targeting cancer anorexia cachexia, currently in Phase 1b/2a, with European patent protection until 2041. It has shown a 6.4% weight gain in cancer patients compared to a 5.4% loss in the placebo group [6][8][9] - **ART26.12**: A FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, which has completed Phase 1 with no serious adverse events and is preparing for multiple ascending dose studies [10][11][13] - **ART12.11**: A proprietary CBD/tetramethylpyrazine cocrystal with improved pharmacokinetics, entering Phase 1 with favorable regulatory guidance from the UK MHRA [15][16][17] Regulatory Environment - Recent regulatory shifts, including a Presidential executive order expanding CBD research and a Medicare pilot program for CBD reimbursement, create favorable conditions for Artelo's clinical development [19][20][22] Market Opportunities - The total addressable market for Artelo's programs is significant, with the global glaucoma market projected to reach $16.3 billion by 2033, and a notable unmet need in cancer cachexia due to the lack of FDA-approved treatments [24] Intellectual Property - Artelo's strong patent position provides long-term protection for its compounds, with ART27.13's European patent extending through 2041, enhancing its attractiveness for potential partnerships [25][26] Partnership Signals - The company has received unsolicited partnership inquiries from global pharmaceutical companies, indicating external validation of its scientific credibility and potential for collaboration [27][29] Capital Efficiency - Artelo operates with a lean structure, directing a significant portion of its budget to R&D while minimizing overhead costs, which allows for efficient capital use [33][34] Future Milestones - Key upcoming milestones include the commencement of Phase 1 studies for ART12.11 and multiple ascending dose enrollment for ART26.12, with ongoing Phase 2 trials for ART27.13 [30][31]

Core Insights - EDAP TMS SA reported record revenue for its High-Intensity Focused Ultrasound (HIFU) business in Q4 and full-year 2025, driven by strong demand for the Focal One Robotic HIFU system [1][4][10]. Financial Performance - Total revenue for the HIFU business in Q4 2025 was €11.7 million ($13.5 million), a 34% increase from €8.8 million ($9.4 million) in Q4 2024 [4]. - Full-year 2025 HIFU revenue reached €33.1 million ($37.4 million), marking a 39% increase compared to €23.8 million ($25.8 million) in 2024 [10]. - Total worldwide revenue for Q4 2025 was €18.9 million ($21.9 million), a slight decrease of 7% from €20.3 million ($21.8 million) in Q4 2024 [6]. - For the full year 2025, total worldwide revenue was €62.4 million ($70.5 million), down 3% from €64.1 million ($69.4 million) in 2024 [12]. System Sales and Growth - In Q4 2025, the company achieved a record of 15 net system placements for the Focal One, with 14 being cash sales and one an operating lease [2]. - Full-year 2025 saw a 69% year-over-year growth in Focal One system placements [8]. - The number of Focal One procedures in the U.S. grew by 28% year-over-year in Q4, indicating a growing adoption of focal therapy among urologists [4][8]. Revenue Guidance - The company reiterated its 2026 revenue guidance of $72.0 million to $80.0 million, with core HIFU business revenue expected to grow between 34% and 45% year-over-year [3][8]. Operating Performance - Gross margin for Q4 2025 was 42.6%, down from 44.8% in Q4 2024, primarily due to tariffs on imports and inventory reserves [7]. - Operating loss for Q4 2025 was €5.2 million ($6.0 million), compared to €3.7 million ($4.0 million) in Q4 2024 [9]. - Full-year 2025 operating loss was €21.9 million ($24.7 million), slightly higher than the €20.5 million ($22.2 million) loss in 2024 [14]. Cash Position - As of December 31, 2025, the company held cash and cash equivalents of €17.4 million ($20.5 million), a decrease from €29.8 million ($31.0 million) at the end of 2024 [15].

VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce the third batch of results from its ongoing exploration at the wholly owned Langis Silver Project, located in the historic silver mining camp of Cobalt, Ontario, Canada. The 2026 drill campaign marks a significant milestone, targeting both infill and expansion of established high-grade silver zones. To date, a total of 8,282 metres across 4 ...

Company Overview - DelphX Capital Markets Inc. is a technology and financial services company focused on developing and distributing next-generation structured products [2] - The company operates through its special purpose vehicle, Quantem LLC, enabling broker-dealers to offer new private placement securities that provide both fixed-income and cryptocurrency-based solutions [2] Stock Options Grant - The Board of Directors of DelphX has approved the grant of 1,450,000 stock options to eligible participants under its stock option plan [1] - The options have a two-year maturity and are exercisable for common shares at an exercise price of $0.08 per share [1] - Of the total options granted, 700,000 were allocated to insiders, including board members and executive officers [1] Proprietary Securities - DelphX's proprietary securities include Collateralized Put Options (CPOs) and Collateralized Reference Notes (CRNs) [5] - CPOs provide secured protection against rating downgrades of corporate bonds and losses in cryptocurrency holdings [5] - CRNs allow investors to assume capped downgrade or cryptocurrency-loss exposure in exchange for attractive returns [5]

Core Viewpoint - Base Carbon Inc. has successfully issued 639,609 carbon credits from the Rwanda Cookstoves Project, marking a significant milestone in its operations and the transition to Verra's VM0050 methodology, which enhances the project's compliance and marketability in carbon offsetting markets [1][2][4]. Group 1: Carbon Credit Issuance - The issuance of 639,609 carbon credits is the fourth from the Rwanda Cookstoves Project and the first under the updated VM0050 methodology, indicating a successful transition and operational reliability [1][2]. - The carbon credits are expected to receive CORSIA eligible tagging after the purchase of required insurance, which will enhance their compliance alignment and market value [1][2]. Group 2: Market Engagement and Sales Strategy - Following confirmation of CORSIA-eligible tagging, the credits will be available for sale in global aviation carbon offsetting markets, with ongoing sales discussions and RFP processes with potential buyers [3]. - The company aims to balance near-term revenue generation with long-term inventory value maximization, leveraging its strong financial position and growing portfolio of eligible carbon credits [3][4]. Group 3: Project Development and Future Outlook - The successful transition to VM0050 methodology reflects the full maturation of the Rwanda Cookstoves Project, positioning the company favorably within the global compliance carbon market [4]. - The company anticipates regular issuance of CORSIA-eligible credits, supported by an attractive supply and demand environment during CORSIA's first compliance period [4].

Core Insights - Aecon Group Inc. has secured a US$691 million contract with the U.S. Army Corps of Engineers for the Howard A. Hanson Dam Additional Water Storage Fish Passage Facility project, with Aecon holding a 40% stake in the joint venture [1] - The project is set to commence construction in the second quarter of 2026 and is expected to be completed by the third quarter of 2031 [2] - The project aims to enhance water storage capacity and improve fish passage, benefiting both the local ecosystem and regional economic growth [4] Company Overview - Aecon Group Inc. is a North American construction and infrastructure development company, providing integrated solutions across various sectors including Civil, Urban Transportation, Nuclear, Utility, and Industrial [5] - The company emphasizes its capabilities in civil and dam infrastructure, positioning itself for steady growth across North America [4] Project Details - The project involves constructing a downstream dam facility with vertically stacked ports, which will support connections to spawning habitats upstream [3] - The Howard A. Hanson Dam is crucial for flood defense in the Green River Valley, having significantly reduced peak flood levels during record flows in December 2025 [4]

Core Insights - Rekor Systems, Inc. has appointed Marc Segal as the Technical Account Management Director for Rekor Command®, enhancing its leadership team in real-time traffic operations and incident management [1][3]. Company Developments - Marc Segal's appointment is strategic, as he is based in Austin, Texas, a key market for transportation innovation, aligning with Rekor's expansion in the state [2]. - Rekor Command® has a statewide blanket purchase order with the Texas Department of Transportation (TxDOT), allowing for deployment across TxDOT districts [2]. - The company aims to leverage Segal's extensive experience in transportation systems to enhance the development and expansion of Rekor Command®, focusing on real-time operational intelligence for transportation agencies [2][5]. Product and Technology - Rekor Command® integrates data from various sources, including traffic sensors and video feeds, to improve incident detection and coordination among jurisdictions [4]. - The company has moved its engineering and product operations from Israel to the U.S., resulting in faster product updates, better customer service, and improved compliance with domestic regulations [6]. Market Position - The presence of Rekor in Texas is expected to accelerate the adoption of Rekor Command® and strengthen engagement with state and local agencies [4]. - The company is positioned to provide actionable intelligence that enhances safety and mobility outcomes in transportation [5].

Core Insights - Fredonia Mining Inc. has engaged market making and investor relations services to enhance its capital markets presence as it advances exploration at its El Dorado-Monserrat gold/silver project in Santa Cruz, Argentina [1] Market Making Services - On March 24, 2026, Fredonia engaged ICP Securities Inc. for automated market making services, with a monthly fee of $7,500 plus applicable taxes [2] - The agreement with ICP is for an initial term of four months, automatically renewing for one-month terms unless terminated with 30 days written notice [2][3] - ICP will manage temporary imbalances in supply and demand for Fredonia's shares, covering its own costs without third-party funding [3] Investor Relations Advisory Agreement - Fredonia has engaged TLG Growth Capital Corp. and Outcrop Mining Capital Corp. as investor relations and capital markets strategy advisors for a six-month term [4] - Each advisor will receive a monthly retainer of $5,000, totaling $10,000 per month, plus applicable taxes, funded from cash on hand [6] - The advisors will also receive 200,000 common share purchase options each, exercisable at $0.475 per share over two years, vesting in four equal tranches [6] Company Overview - Fredonia holds approximately 18,300 hectares of gold and silver license areas in the Deseado Massif geological region, including the El Dorado-Monserrat project, which is near AngloGold Ashanti's Cerro Vanguardia mine [9]

Core Insights - Marvel Biosciences Corp. has selected Novotech as the contract research organization for its upcoming Phase I clinical trial of the lead drug candidate MB-204, which targets autism spectrum disorder and related conditions [1][2] - The partnership with Novotech is expected to enhance the efficiency of the Phase I program due to Australia's favorable regulatory environment and significant tax credits [2] Company Overview - Marvel Biosciences Corp. is a Calgary-based biotechnology company focused on developing new treatments for neurological diseases and neurodevelopmental disorders, with its lead drug candidate MB-204 being a novel adenosine A2A antagonist [3] - MB-204 is a fluorinated derivative of Istradefylline, an approved Parkinson's drug, and is being explored for its potential in treating conditions such as autism, depression, and rare disorders like Rett syndrome and Fragile X syndrome [3]

Core Viewpoint - Bessor Minerals Inc. has terminated its asset purchase agreement for the Jagrite Graphite Project in British Columbia, following a previous announcement made in September 2025 [1]. Company Overview - Bessor Minerals Inc. is focused on the exploration and development of its Golden Eagle property in the Yukon and the Redhill volcanogenic massive sulphide deposit in British Columbia [2]. - The company holds a 1% Net Smelter Return (NSR) on certain claims in the Blackwater Mine, which is operated by Artemis Gold Inc. [2].